Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, hypertension, and kidney disease ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Valentine’s Day has come and gone, but it’s never too late to focus on your heart health.  A groundbreaking new study ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

In a powerful act of love and sacrifice, Julie Malliet donated her kidney to her husband, Dave, who had been battling chronic kidney disease for years.

Cardiovascular diseases claim more lives in the U.S. than all forms of cancer and accidental deaths combined, according to ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Humana and Monogram Health, a value-based multispecialty provider of in-home care and benefit management services for patients living with kidney disease, have expanded their partnership to patients ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...